TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit [Yahoo! Finance]
TuHURA Biosciences, Inc. (HURA)
Company Research
Source: Yahoo! Finance
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. On 31 December 2025, the US$114m market-cap company posted a loss of US$30m for its most recent financial year. As path to profitability is the topic on TuHURA Biosciences' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Consensus from 4 of the American Biotechs analysts is that TuHURA Biosciences is on the verge of breakeven. They anticipate the company to incur a final loss in 2027, before generating positive profits of US$968k in 2028. So, the company is predicted to breakeven approximately 2 years from today. What rate w
Show less
Read more
Impact Snapshot
Event Time:
HURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HURA alerts
High impacting TuHURA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
HURA
News
- TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsPR Newswire
- TuHURA Biosciences (HURA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HURA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update [TheStreet.com]TheStreet.com
- TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdatePR Newswire
- TuHURA Biosciences (HURA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=HURA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell"MarketBeat
HURA
Earnings
- 11/14/25 - Beat
HURA
Analyst Actions
- 2/3/26 - HC Wainwright
HURA
Sec Filings
- 4/8/26 - Form 424B5
- 4/8/26 - Form 8-K
- 4/1/26 - Form 8-K
- HURA's page on the SEC website